Eupraxia Pharmaceuticals (EPRX) Consolidated Net Income (2023 - 2026)
Eupraxia Pharmaceuticals' Consolidated Net Income was -$17.02 million in the quarter ended Jun 30, 2026, compared with -$7.41 million a year earlier.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Consolidated Net Income (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Eupraxia Pharmaceuticals' Consolidated Net Income was -$54.46 million through Jun 30, 2026; for the year ended Dec 31, 2025, it came in at -$36.49 million.
- In earlier years, Consolidated Net Income was -$27.2 million in the year ended Dec 31, 2024, -$28.89 million in the year ended Dec 31, 2023 and -$20.27 million in the year ended Dec 31, 2022.
- The figure for the quarter ended Jun 30, 2026 marks the lowest quarterly Consolidated Net Income in data going back to the quarter ended Mar 31, 2023.
- Per Business Quant data, EPRX's Consolidated Net Income in the three quarters before the quarter ended Jun 30, 2026 was -$15.09 million (quarter ended Mar 31, 2026), -$15.47 million (quarter ended Dec 31, 2025) and -$6.88 million (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.62 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -237.00 Mn |
| 10 | Eupraxia Pharmaceuticals | 289.28 Mn | 287.68 Mn | - | -17.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.02 Mn |
| Mar 31, 2026 | -15.09 Mn |
| Dec 31, 2025 | -15.47 Mn |
| Sep 30, 2025 | -6.88 Mn |
| Jun 30, 2025 | -7.41 Mn |
| Mar 31, 2025 | -6.73 Mn |
| Dec 31, 2024 | -8.90 Mn |
| Sep 30, 2024 | -5.87 Mn |
| Jun 30, 2024 | -6.24 Mn |
| Mar 31, 2024 | -6.19 Mn |
| Dec 31, 2023 | -10.60 Mn |
| Sep 30, 2023 | -4.81 Mn |
| Jun 30, 2023 | -9.52 Mn |
| Mar 31, 2023 | -3.96 Mn |
API Access
Eupraxia Pharmaceuticals Consolidated Net Income API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=EPRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "consolidated-net-income", "ticker": "EPRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=EPRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();